Irati Garmendia Iturbe-rekin lankidetzan egindako argitalpenak (4)

2021

  1. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

2019

  1. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899

2018

  1. The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer

    Laboratory Investigation, Vol. 98, Núm. 12, pp. 1562-1574

2014

  1. New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations

    International Journal of Cancer, Vol. 135, Núm. 11, pp. 2516-2527